Aclaris Therapeutics, Inc. - נכסים נקיים למניה בודדת ACRS

The Aclaris Therapeutics (ACRS) price chart reflects the performance of a company whose immunological drug developments are currently in the testing phase, rendering commercial growth unattainable due to high R&D costs. The current value of the metric is 0.90, while operating income is absent and activities are sustained through external funding. The business focuses on developing dermatology therapies, targeting the skin treatment market.

Book value per share reflects the portion of net assets attributable to a single security and serves as an indicator of the issuer's intrinsic value upon liquidation. By analyzing the book value per share ratio, an investor can assess the resource capitalization of Aclaris Therapeutics (ACRS), which, at the clinical trial stage in immunology, is limited by bioreagent costs and compliance with environmental disposal protocols.